Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention
Not Applicable
Completed
- Conditions
- Angioplasty, Transluminal, Percutaneous Coronary
- Interventions
- Registration Number
- NCT00610870
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
The purpose of this study to determine whether statin pretreatment decrease myocardial infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 173
Inclusion Criteria
- Presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset
- ST segment elevation more than 1 mm in two or more contiguous leads or presumably a new onset left bundle branch blockage
Exclusion Criteria
- Cardiogenic shock
- History of myocardial infarction
- Chronic liver disease
- Previous or current statin use
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 atorvastatin Atorvastatin group
- Primary Outcome Measures
Name Time Method Myocardial infarct size by SPECT between 5 and 14 days after acute myocardial infarction
- Secondary Outcome Measures
Name Time Method Myocardial infarct size measured by contrast-enhanced MRI within 14 days after acute myocardial infarction Myocardial blush grade after the procedure immediate after procedure complete ST resolution at 60 minutes after the procedure major adverse cardiac events related to left ventricular dysfunction (death, new-onset sustained hypotension or heart failure, and hospital readmission for left ventricular dysfunction) at 6 months after the procedure
Trial Locations
- Locations (1)
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of